Carvedilol
Hepatitis C Induced Liver Cirrhosis
Explore 3 assets in Hepatitis C Induced Liver Cirrhosis →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Tianjin Second People's Hospital
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04543643CT.gov Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatitis C Induced Liver Cirrhosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Carvedilol (this asset) | Tianjin Second People's Hospital | P3 | B · 60 |
| Umbellatine | Tianjin Second People's Hospital | P3 | B |
| Rosuvastatin | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P2 | CCC |
| Ribavirin | Institute of Liver and Biliary Sciences, India | N/A | D |
| Sofosbuvir | Institute of Liver and Biliary Sciences, India | N/A | D |
| Foscenvivint | Komagome Hospital | P1 | NR |
Other indications for Carvedilol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Portal Hypertension | — | P4 | BBB · 76 |
| Esophageal Varices | — | P4 | BBB · 73 |
| Cirrhosis Of Liver | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Carvedilol in Hepatitis C Induced Liver Cirrhosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/carvedilol-hepatitis-c-induced-liver-cirrhosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →